| Literature DB >> 30782918 |
Bronwyn Myers1,2, Tara Carney1,2, Felicia A Browne3, Wendee M Wechsberg3,4,5,6.
Abstract
OBJECTIVES: Sexual and physical trauma and substance use are intersecting risks for HIV among young women. This study assesses the feasibility, acceptability and preliminary effects of a novel trauma-informed substance use and sexual risk reduction intervention for young South African women.Entities:
Keywords: gender; low-and-middle-income country; mental health; sexual risk; substance use
Year: 2019 PMID: 30782918 PMCID: PMC6368003 DOI: 10.1136/bmjopen-2018-024776
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Participant flow chart.
Baseline demographic and clinical characteristics of the overall sample (n=60) and by treatment completion status
| Variable | Overall | Treatment completion | ||
| Yes (n=21) | No (n=39) | P value | ||
| Sociodemographic variables | ||||
| In a relationship, N (%) | 55 (91.7) | 20 (95.2) | 35 (89.7) | 0.649 |
| Employment (no), N (%) | 55 (91.7) | 20 (95.2) | 35 (89.7) | 0.649 |
| HIV status (positive), N (%) | 28 (46.7) | 9 (42.9) | 19 (48.7) | 0.788 |
| Newly diagnosed as HIV positive (yes), N (%) | 10 (35.7) | 1 (11.1) | 9 (47.4) | 0.06 |
| Sexual abuse (yes), N (%) | 41 (68.3) | 13 (61.9) | 28 (71.8) | 0.562 |
| Physical abuse (yes), N (%) | 55 (91.7) | 19 (90.5) | 36 (92.3) | 0.602 |
| Sexual and physical abuse (yes), N (%) | 34 (56.7) | 10 (47.6) | 24 (61.5) | 0.414 |
| Substance use outcomes | ||||
| Days of heavy drinking in past month, M (SD) | 8.2 (6.4) | 8.1 (6.0) | 8.3 (6.7) | 0.906 |
| Days of cannabis use in past month, M (SD) | 11.4 (11.9) | 10.4 (11.7) | 11.8 (12.1) | 0.715 |
| Days of methamphetamine in past month, M (SD) | 18.4 (11.6) | 13.5 (13.2) | 20.2 (10.7) | 0.227 |
| Days of methaqualone use in past month, M (SD) | 14.0 (11.9) | 11.1 (13.1) | 15.1 (11.6) | 0.498 |
| Cannabis positive (biological), N (%) | 30 (50.0) | 9 (42.9) | 21 (53.8) | 0.589 |
| Methamphetamine positive (biological), N (%) | 27 (45.0) | 8 (38.1) | 19 (48.7) | 0.587 |
| Methaqualone positive (biological), N (%) | 29 (48.3) | 8 (38.1) | 21 (53.8) | 0.287 |
| Opiate positive (biological), N (%) | 4 (6.7) | 0 (0.0) | 4 (6.7) | 0.287 |
| Mental health outcomes | ||||
| CES-D, M (SD) | 26.1 (9.5) | 27.4 (11.1) | 25.4 (8.6) | 0.489 |
| K-10, M (SD) | 25.7 (6.8) | 25.1 (7.6) | 25.9 (6.5) | 0.693 |
| Trauma symptom, M (SD) | 33.6 (5.6) | 34.9 (7.6) | 31.9 (7.4) | 0.154 |
| MOS-SSS, M (SD) | 60.1 (13.6) | 59.2 (14.4) | 61.3 (13.4) | 0.593 |
| Sexual risk outcomes | ||||
| Number of partners in last month, M (SD) | 1.7 (1.5) | 1.5 (0.7) | 1.9 (1.8) | 0.204 |
| Condom use last sex (yes), N (%) | 10 (16.9) | 2 (10.0) | 8 (20.5) | 0.469 |
| Number of STI symptoms in last month, M (SD) | 1.2 (0.9) | 1.2 (0.6) | 0.9 (1.1) | 0.159 |
CES-D, Centre for Epidemiologic Studies Depression Scale; K-10, 10-item Kessler Psychological Distress Scale; MOS-SSS, Medical Outcomes Study Social Support Survey; STI, sexually transmitted infection.
Change in substance use, mental health and sex risk outcomes for the overall sample (n=56) and by intervention exposure
| Outcomes | Overall sample (n=56) | Intervention dosage of up to and including four sessions (n=23) | Intervention dosage of five or more sessions (n=33) | ||||
| Baseline | 3-month follow-up | Baseline to follow-up | Baseline | 3-month follow-up | Baseline | 3-month follow-up | |
| Substance use outcomes | M (SD) | M (SD) | M (SD) | M (SD) | M (SD) | M (SD) | |
| Days of heavy drinking in past month | 8.4 (6.1) | 5.3 (6.9) | 3.2 (0.9 to 5.4)* | 8.8 (6.7) | 6.7 (8.2) | 8.1 (5.8) | 4.3 (5.8)* |
| Days of cannabis use in past month | 12.3 (12.4) | 6.0 (9.2) | 6.3 (2.6 to 9.9)* | 14.1 (13.5) | 4.7 (7.7)* | 11.1 (11.5) | 6.7 (9.8)* |
| Days of methamphetamine in past month | 19.5 (11.0) | 11.7 (11.3) | 7.8 (1.8 to 13.7)* | 22.0 (9.3) | 9.2 (11.4)* | 17.0 (12.3) | 14.2 (11.0) |
| Days of methaqualone in past month | 14.9 (11.8) | 9.9 (11.4) | 4.9 (−0.7 to 10.5) | 15.3 (10.6) | 7.6 (9.5)* | 14.4 (13.6) | 12.5 (13.2) |
| Cannabis positive (biological), N (%) | 26 (46.4) | 21 (37.5%)* | − | 13 (56.5) | 11 (47.8)* | 13 (39.4) | 10 (30.3)* |
| Methamphetamine positive (biological), N (%) | 25 (44.6) | 20 (35.7%)* | − | 11 (47.8) | 9 (39.1)* | 14 (42.4) | 11 (33.3)* |
| Methaqualone positive (biological), N (%) | 27 (48.2) | 21 (37.5)* | − | 13 (56.5) | 10 (43.5)* | 14 (42.4) | 11 (33.3)* |
| Mental health outcomes | |||||||
| CES-D score | 26.3 (9.6) | 17.7 (7.3) | 8.5 (5.3 to 11.7)* | 24.7 (8.9) | 17.3 (7.5)* | 27.5 (10.1) | 18.1 (7.2)* |
| K-10 score | 25.7 (6.9) | 17.8 (7.3) | 7.9 (5.6 to 10.3)* | 25.4 (7.2) | 17.6 (8.3)* | 25.9 (6.8) | 17.7 (6.5)* |
| Trauma symptom score | 32.9 (7.6) | 21.7 (8.6) | 11.2 (8.8 to 13.6)* | 33.9 (3.5) | 22.2 (7.8)* | 33.4 (6.7) | 21.7 (9.2)* |
| MOS-SSS | 60.6 (14.1) | 63.5 (15.7) | −2.8 (−6.7 to 1.1) | 60.5 (14.5) | 63.8 (16.6) | 60.8 (14.1) | 63.3 (15.3) |
| Sex risk outcome | |||||||
| Number of partners in last month | 1.7 (1.1) | 1.0 (0.4) | 0.6 (0.3 to 1.1)* | 2.1 (2.2) | 1.2 (0.7)* | 1.4 (0.6) | 0.9 (0.4)* |
| Condom use at last sex, N (%) | 8 (14.5) | 25 (45.5) | − | 2 (8.7) | 10 (43.5) | 6 (18.8) | 15 (46.9) |
| STI symptoms in past month | 1.1 (0.9) | 0.2 (0.8) | 0.8 (0.5 to 1.2)* | 0.8 (1.1) | 0.3 (1.0)* | 1.3 (0.8) | 0.2 (0.6)* |
*Significant at p<0.05.
CES-D, Centre for Epidemiologic Studies Depression Scale; K-10, 10-item Kessler Psychological Distress Scale; MOS-SSS, Medical Outcomes Study Social Support Survey; STI, sexually transmitted infection.